BeOne Medicines (BEIGF) Retained Earnings (2015 - 2026)

BeOne Medicines (BEIGF) has reported Retained Earnings for 12 consecutive years, with $13.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings rose 5.32% year-over-year to $13.1 billion in Q2 2026; TTM through Jun 2026 was $13.1 billion, a 5.32% increase from a year earlier, with the FY2025 full-year figure at $12.8 billion, up 5.55% from the prior year.
• Retained Earnings was $13.1 billion for Q2 2026 at BeOne Medicines, up from $12.9 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $13.1 billion in Q2 2026 and troughed at $11.3 billion in Q1 2022.
• A 5-year average of $12.0 billion and a median of $11.8 billion in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings surged 50.51% in 2022 and climbed 0.45% in 2023, its largest moves.
• Over 5 years, Retained Earnings stood at $11.5 billion in 2022, then gained by 0.5% to $11.6 billion in 2023, then increased by 4.22% to $12.1 billion in 2024, then climbed by 5.55% to $12.8 billion in 2025, then climbed by 2.32% to $13.1 billion in 2026.
• The last three Retained Earnings figures came in at $13.1 billion (Q2 2026), $12.9 billion (Q1 2026), and $12.8 billion (Q4 2025), per Business Quant data.